Around the world, people suffer from a genetic condition called hemophilia. Even with expensive and time-consuming treatments, simple injuries for these patients hold the threat of turning into serious complications and even life-threatening events. But now, one biotech company has stumbled upon what very early trials suggest could be a "cure" -- something that, with a single intravenous drip, essentially corrects the genetic mutation that causes the disorder. This week, Bloomberg's Doni Bloomfield visits the scientists behind this treatment and a patient who has actually tried it. If it works, researchers may have pushed the door open to a whole new world of treatments that tackle these diseases at their source: our DNA.

See omnystudio.com/listener for privacy information.